Skip to main content
MedinCell S.A. logo

MedinCell S.A. — Investor Relations & Filings

Ticker · MEDCL ISIN · FR0004065605 LEI · 969500R79U6PXCL2FF46 PA Manufacturing
Open in API
Filings indexed 522 across all filing types
Latest filing 2023-12-11 Report Publication Anno…
Country FR France
Listing PA MEDCL

About MedinCell S.A.

https://www.medincell.com/en/

MedinCell S.A. is a pharmaceutical company at the commercial stage that specializes in the development of long-acting injectable (LAI) therapies. The company's core is its proprietary BEPO® technology platform, which enables the controlled and sustained release of active pharmaceutical ingredients over periods ranging from days to months after a single injection. This technology forms a fully biodegradable depot in situ, designed to improve treatment efficiency, enhance patient compliance, and increase the global accessibility of medicines. MedinCell develops a portfolio of LAI products across various therapeutic areas, including psychiatry, advancing its pipeline through both internal research and strategic partnerships with other pharmaceutical organizations.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Report Publication Announcement Classification · 98% confidence The document is a short announcement (2461 characters) dated December 11, 2023, stating that MedinCell will hold a videoconference on December 19th, 2023, to present its 'half-year financial results (April 2023-September 2023)'. This structure—announcing the date and time of a presentation for upcoming results—fits the definition of a Report Publication Announcement (RPA), as it is not the comprehensive report itself (which would be an IR) but an announcement about its presentation. It explicitly announces the publication/presentation event.
2023-12-11 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 90% confidence The document is a short announcement (2617 characters) dated December 11, 2023, stating that MedinCell will hold a conference call on December 19, 2023, to present its 'résultats financiers semestriels' (semi-annual financial results) for the period April 2023 - September 2023. This is an announcement about an upcoming event where financial results will be discussed, not the comprehensive report itself (which would be an IR or 10-K/AR). Since it is announcing the presentation of results, it is closely related to an Earnings Release (ER) or an Interim Report (IR). However, the primary action described is the scheduling of a conference call to discuss these results, which often accompanies an Earnings Release (ER) or serves as the primary means of dissemination for interim results when the full report isn't attached. Given the focus on the *presentation* of semi-annual results via a conference call, and the short length, it functions as a notification about the upcoming release/discussion of periodic financial performance. If the full report were attached, it would be IR. Since it is an announcement *about* the presentation of semi-annual results, it aligns best with the function of an Earnings Release (ER) announcement, or potentially a Report Publication Announcement (RPA) if it were only announcing the *release* date. Because it explicitly mentions the presentation of 'résultats financiers semestriels' via a conference call, it is classified as an Earnings Release (ER) announcement, as this is the standard context for such calls, even if the period is semi-annual rather than quarterly. H2 2023
2023-12-11 French
Informations privilégiées / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information mensuelle relative au nombre d'actions composant le capital social et au nombre total des droits de vote" (Monthly information relating to the number of shares comprising the share capital and the total number of voting rights), dated December 5, 2023, and references Article 223-16 of the AMF General Regulation. It explicitly provides a table detailing the number of outstanding shares and the total gross and net voting rights as of November 30th. This content directly relates to changes in share capital structure and voting rights, which aligns best with the 'Share Issue/Capital Change' (SHA) category, although it is a periodic update on the share count rather than a new issue announcement. However, given the specific options, this type of mandatory monthly disclosure regarding the total number of shares and voting rights is often categorized under capital structure updates. If a more specific 'Share Capital Disclosure' existed, it would fit there, but SHA is the closest fit among the provided codes for disclosures about the total number of shares outstanding.
2023-12-05 French
Inside Information / Other news releases
Report Publication Announcement Classification · 98% confidence The document is very short (2041 characters) and its primary purpose is to announce a change in the publication date for the company's half-year results (for the period April-September 2023). It explicitly states, 'MedinCell will publish its half-year results... on 19 December 2023' and details the postponement. This fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports, rather than being the comprehensive report itself (which would be an Interim/Quarterly Report, IR).
2023-11-20 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 99% confidence The document is a short announcement dated November 20, 2023, stating that MedinCell will publish its half-year results (for April - September 2023) on December 19, 2023, noting a postponement from the original date. Since the document is short and its primary function is to announce the future publication date and details of a financial report (the half-year results), it fits the definition of a Report Publication Announcement (RPA). It is not the comprehensive Interim/Quarterly Report (IR) itself, nor is it an Earnings Release (ER) which typically contains the actual results.
2023-11-20 French
Informations privilégiées / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information mensuelle relative au nombre d'actions composant le capital social et au nombre total des droits de vote" (Monthly information relating to the number of shares comprising the share capital and the total number of voting rights). It explicitly references Article 223-16 of the AMF General Regulation and provides a table detailing the number of shares and voting rights as of October 31st. This content directly relates to changes in share capital and voting rights, which aligns best with the 'Share Issue/Capital Change' category (SHA) or potentially a general regulatory filing (RNS). However, since it is a specific, recurring report on capital structure and voting rights, SHA is the most precise fit among the specialized codes, although it is not explicitly listed as a standard SEC form. Given the options, 'SHA' (Share Issue/Capital Change) covers changes in the number of shares and voting rights, which is the core subject matter. It is not a dividend announcement (DIV), director dealing (DIRS), or major shareholding notification (MRQ). It is a specific regulatory disclosure about the capital base.
2023-11-15 French

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.